# Who does Bristol-Myers Squibb Company pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/bristol-myers-squibb · Facet: suppliers · Updated: 2026-09-11T18:43:29.256621+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Bristol-Myers Squibb Company's confirmed suppliers/cost counterparties include Samsung Biologics plus 1 undisclosed/aggregate relationship. Per the valuechain.wiki graph: 2 cost edges, backed by 3 dated sources, 0 of them primary filings (as of 2026-09-11).

### 카루나 테라퓨틱스 (high)
- metric: Amount $14B · acquisition completed 2024-03-18 · Total consideration for the acquisition of Karuna Therapeutics
- note: BMS acquired Karuna Therapeutics in March 2024 to obtain Cobenfy, a schizophrenia treatment with a novel mechanism of action. Total consideration was $14.0 billion, and Karuna became a wholly owned BMS subsidiary.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-11) https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm: "BMS acquired all Karuna common stock in an all-cash transaction for total consideration of $14.0 billion."
- [confirms] Meritz Securities Research Center (KO, research, published 2024-03-19) https://home.imeritz.com/include/resource/research/WorkFlow/20240318154038001K_02.pdf: "The BMS-Karuna transaction, valued at $14 billion, was among the megadeals then in progress."
- [confirms] PureTech Health plc (EN, ir, published 2024-03-18) https://investors.puretechhealth.com/news-releases/news-release-details/14b-acquisition-prtcs-karuna-bms-completed: "BMS acquired all outstanding Karuna common stock for $330 per share, for approximately $14 billion in total equity value."

### Cellares (high)
- metric: Contract value $380M · 2024 agreement · Maximum transaction value, including upfront and milestone payments, under the Cellares CAR-T capacity reservation and supply agreement
- note: BMS signed a worldwide capacity reservation and supply agreement with Cellares to manufacture selected CAR-T therapies at clinical and commercial scale. The transaction is valued at up to $380 million in upfront and milestone payments.
- [confirms] Bristol Myers Squibb (EN, ir, published 2024-04-22) https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-and-Cellares-Announce-a-380M-Worldwide-Capacity-Reservation-and-Supply-Agreement-for-the-Manufacture-of-CAR-T-Cell-Therapies-to-Bring-the-Promise-of-Cell-Therapy-to-More-Patients-Faster/default.aspx: "The transaction is valued up to $380M in upfront and milestone payments."

### 삼성바이오로직스 (high)  → /samsung-biologics.md
- metric: Contract value $242M · 2023-2030 · Value of the BMS antibody cancer drug contract manufacturing agreement announced in 2023
- note: BMS contracts Samsung Biologics to manufacture drug substance for a commercial antibody cancer medicine. The agreement announced in 2023 was valued at $242 million through 2030.
- [confirms] Yonhap News Agency (KO, news, published 2023-09-18) https://www.yna.co.kr/view/AKR20230918037800017: "Samsung Biologics disclosed a $242 million contract manufacturing agreement with BMS."
- [confirms] Samsung Biologics (EN, ir, published 2023-09-18) https://samsungbiologics.com/media/company-news/samsung-biologics-announces-expanded-strategic-agreement-with-bristol-myers-squibb: "Samsung Biologics will provide drug substance manufacturing for an antibody cancer drug substance at Plant 4."

Reverse side: https://valuechain.wiki/bristol-myers-squibb/customers.md · Ripple: https://valuechain.wiki/bristol-myers-squibb/ripple.md

---
Full node: https://valuechain.wiki/bristol-myers-squibb.md · JSON: https://valuechain.wiki/bristol-myers-squibb.json